20:41 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting GDF11 could help treat osteoporosis. In a mouse model of estrogen deficiency-induced bone loss, an anti-GDF11 mAb increased the number, thickness and volume of trabeculae in the distal femur...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

UX023: Extension study data

Data from 22 patients with XLH who received once-monthly 0.1-1 mg/kg subcutaneous KRN23 in the 12-month, open-label INT-002 extension of the 4-month, open-label, dose-escalation, U.S. and Canadian Phase I/II INT-001 trial showed that increases in...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

UX023: Phase I/II data

The open-label, dose-escalation, U.S. and Canadian Phase I/II INT-001 trial in 28 adults with XLH showed that once-monthly 0.05-0.6 mg/kg doses of subcutaneous KRN23 increased urinary phosphorus reabsorption, serum phosphorus levels and 1,25 dihydroxy vitamin...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

MIV-711: Phase I data

A double-blind, placebo-controlled Phase I trial in 27 healthy volunteers showed that once-daily oral MIV-711 reduced serum levels of the bone resorption biomarker c-terminal telopeptide of type I collage ( CTX-I ) from baseline to...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

MIV-711: Phase Ia data

A double-blind, placebo-controlled Phase Ia trial in 27 healthy volunteers showed that 20-600 mg oral MIV-711 was well tolerated with no adverse events reported. MIV-711 reduced serum levels of c-terminal telopeptide of type I collagen...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Oral salmon calcitonin: Phase II data

The double-blind, U.S. Phase II TAR01-201 trial in 129 postmenopausal women with low bone mass at an increased risk of fracture showed that once-daily 200 mg oral Ostora met the primary endpoint of superiority to...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

Ostora oral salmon calcitonin: Additional Phase III data

Additional data from the double-blind, double-dummy, international Phase III ORACAL trial in 565 postmenopausal women showed that once-daily oral Ostora significantly reduced levels of fasting C-terminal telopeptide of type I collagen (CTX-I) , a biomarker...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Prolia denosumab: Extension study data

An open-label extension of a 2-year Phase II trial in 200 patients showed that BMD at the lumbar spine and total hip in patients who received Prolia for 8 years (n=80) increased by an average...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

Prolia Denosumab: Phase III data

In its 2Q11 earnings, Amgen said data from the double-blind Phase III ADAMO trial in 242 men with osteoporosis showed that 60 mg Prolia denosumab met the primary endpoint of a significantly greater percent change...
08:00 , Jan 24, 2011 |  BC Week In Review  |  Clinical News

ViaDerm-Calcitonin: Phase I data

An open-label, crossover Phase I trial in 12 postmenopausal women showed that single doses of 60-300 µg ViaDerm-Calcitonin significantly reduced levels of the bone resorption and cartilage degradation biomarkers C-terminal telopeptide of type I collagen...